Table 1 Baseline characteristics and demographics for patients enrolled in phase 1 (n = 43)
| Â | Pacritinib | |||||||
|---|---|---|---|---|---|---|---|---|
100Â mg | 150Â mg | 200Â mg | 300Â mg | 400Â mg | 500Â mg | 600Â mg | All patientsa | |
n = 3 | n = 6 | n = 9 | n = 6 | n = 6 | n = 7 | n = 6 | n = 43 | |
Median age, years (range) | 72.0 (59–78) | 76.0 (66–86) | 69.0 (63–76) | 64.5 (50–77) | 67.5 (52–83) | 65.0 (49–77) | 74.5 (53–76) | 71.0 (49–86) |
Male, n (%) | 2 (66.7) | 5 (83.3) | 7 (77.8) | 3 (50.0) | 2 (33.3) | 4 (57.1) | 4 (66.7) | 27 (62.8) |
ECOG PS, n (%) | ||||||||
 0 | 0 | 2 (33.3) | 5 (55.6) | 4 (66.7%) | 3 (50.0) | 4 (57.1) | 0 | 18 (41.9) |
 1 | 2 (66.7) | 2 (33.3) | 4 (44.4) | 1 (16.7) | 2 (33.3) | 2 (28.6) | 5 (83.3) | 18 (41.9) |
 2 | 1 (33.3) | 2 (33.3) | 0 | 1 (16.7) | 1 (16.7) | 1 (14.3) | 1 (16.7) | 7 (16.3) |
Median disease duration, months (range) | 5.0 (4.1–6.7) | 25.8 (8.6–174.4) | 45.9 (2.3–410.2) | 37.4 (8.5–341.8) | 27.4 (5.1–132.2) | 36.9 (10.0–182.9) | 99.2 (13.7–196.9) | 36.9 (2.3–410.2) |
Current malignancy type, n (%) | ||||||||
 AML | 0 | 3 (50.0) | 0 | 0 | 3 (50.0) | 0 | 1 (16.7) | 7 (16.3) |
   JAK2 mutationb, n/N (%) | – | 1/3 (33.3) | – | – | 2/3 (66.7) | – | 1/1 (100) | 4/7 (57.1) |
 Myelofibrosis | 3 (100.0) | 3 (50.0) | 9 (100.0) | 6 (100.0) | 3 (50.0) | 7 (100.0) | 5 (83.3) | 36 (83.7) |
   JAK2 mutationb, n/N (%) | 2/3 (66.7) | 2/3 (66.7) | 8/9 (88.9) | 5/6 (83.3) | 3/3 (100) | 5/7 (71.4) | 4/5 (80.0) | 29/36 (80.6) |
  Median prior systemic therapies, n (range) | 1.0 (0–4) | 3.0 (2–4) | 1.0 (0–4) | 2.0 (1–4) | 2.0 (1–4) | 2.0 (0–4) | 3.0 (1–4) | 3.0 (0–4) |
  Median time since last cancer treatment, months (range) | 2.4 (1.5–3.2) | 1.2 (0.1–6.3) | 2.0 (0.5–39.6) | 8.0 (0.5–37.1) | 1.5 (0.5–2.4) | 2.8 (0.7–27.1) | 6.3 (0.6–21.7) | 2.2 (0.1–39.6) |